First National Bank & Trust Co. of Newtown Has $1.55 Million Stake in Bristol-Myers Squibb (NYSE:BMY)

First National Bank & Trust Co. of Newtown decreased its stake in Bristol-Myers Squibb (NYSE:BMY) by 1.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,260 shares of the biopharmaceutical company’s stock after selling 595 shares during the quarter. First National Bank & Trust Co. of Newtown’s holdings in Bristol-Myers Squibb were worth $1,553,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. True Wealth Design LLC bought a new position in Bristol-Myers Squibb in the 4th quarter valued at $26,000. Coppell Advisory Solutions Corp. bought a new position in Bristol-Myers Squibb in the 4th quarter valued at $31,000. Coppell Advisory Solutions LLC bought a new position in Bristol-Myers Squibb in the 2nd quarter valued at $28,000. Live Oak Investment Partners bought a new position in Bristol-Myers Squibb in the 4th quarter valued at $33,000. Finally, OFI Invest Asset Management bought a new position in Bristol-Myers Squibb in the 3rd quarter valued at $25,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Up 0.6 %

NYSE BMY traded up $0.31 on Friday, reaching $48.61. The company had a trading volume of 2,803,687 shares, compared to its average volume of 15,608,562. The company has a quick ratio of 1.31, a current ratio of 1.43 and a debt-to-equity ratio of 1.24. The stock has a market cap of $98.52 billion, a price-to-earnings ratio of 12.56, a PEG ratio of 1.44 and a beta of 0.39. The stock’s 50 day moving average is $51.25 and its 200-day moving average is $51.57. Bristol-Myers Squibb has a 52 week low of $47.58 and a 52 week high of $70.93.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.55 by $0.15. The company had revenue of $11.48 billion during the quarter, compared to analysts’ expectations of $11.19 billion. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. Bristol-Myers Squibb’s revenue for the quarter was up .6% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.82 earnings per share. Equities analysts predict that Bristol-Myers Squibb will post 6.63 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.94%. Bristol-Myers Squibb’s dividend payout ratio is currently 62.18%.

Wall Street Analyst Weigh In

Several brokerages have issued reports on BMY. Redburn Atlantic downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price objective for the company from $77.00 to $54.00 in a research report on Tuesday, February 6th. StockNews.com downgraded Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Wells Fargo & Company boosted their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday. Finally, William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average target price of $61.18.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.